In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...

Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...

Watch parts 1 and 2 of our conversation with Dr Collins.

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.

Follow-up analysis from Argenica’s Phase II stroke trial shows promising functional improvements in patients treated with ARG ...

Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

Univariate analysis showed that factors such as grade level, family economic status, reasons for choosing nursing major, exposure to AI related courses/training, and daily AI usage time had ...

Among a small cohort of children and adolescents with autism spectrum disorder, a 12-week course of memantine led to improved ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data ...